Frontiers in Medicine (Mar 2024)

Therapeutic development targeting host heparan sulfate proteoglycan in SARS-CoV-2 infection

  • Qi Zhang,
  • Ivan Pavlinov,
  • Yihong Ye,
  • Wei Zheng

DOI
https://doi.org/10.3389/fmed.2024.1364657
Journal volume & issue
Vol. 11

Abstract

Read online

The global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent need for effective therapeutic options. SARS-CoV-2 is a novel coronavirus responsible for the COVID-19 pandemic that has resulted in significant morbidity and mortality worldwide. The virus is known to enter host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor, and emerging evidence suggests that heparan sulfate proteoglycans (HSPGs) play a crucial role in facilitating this process. HSPGs are abundant cell surface proteoglycan present in many tissues, including the lung, and have been shown to interact directly with the spike protein of SARS-CoV-2. This review aims to summarize the current understanding of the role of HSPGs in SARS-CoV-2 infection and the potential of developing new therapies targeting HSPGs.

Keywords